Research Paper Volume 13, Issue 4 pp 5034—5054

Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism

TRIM29 is upregulated in colorectal cancer. (A) The expression of CDH3, CST1, KLK6 and TRIM29 is upregulated in colorectal cancer (CRC) tissues and cell lines. (B) Immunohistochemistry (IHC) results showed that CDH3, CST1, KLK6 and TRIM29 expression was upregulated in CRC. (C) Representative IHC images of TRIM29 expression. (D) Statistical data graph of patients with different TRIM29 expression levels in CRC tissues and noncancerous samples (PE) Statistical data graph of patients with or without lymph node metastasis stratified by TRIM29 expression level (P=0.018). (F) Statistical data graph of patients at different stages stratified by TRIM29 expression level (PG) Kaplan-Meier curves for CRC patients according to TRIM29 expression levels. The statistical analysis was performed using the chi-square test (P=0.005). (H) IHC results showed that TRIM29 is expressed at much higher levels in RSCC than in LSCC (PI) qPCR was used to measure the relative expression levels of TRIM29 in CRC samples and their matched noncancerous samples (PJ) The qPCR results showed that TRIM29 is expressed at much higher levels in RSCC than in LSCC (PK) Western blotting was used to detect TRIM29 expression in 8 pairs of samples. The statistical analysis was performed using the chi-square test (D–F, H) and two-tailed Student’s t-test (I, J). The error bars represent the SEM. Kaplan-Meier method compared with a log-rank test. *P P P P

Figure 1. TRIM29 is upregulated in colorectal cancer. (A) The expression of CDH3, CST1, KLK6 and TRIM29 is upregulated in colorectal cancer (CRC) tissues and cell lines. (B) Immunohistochemistry (IHC) results showed that CDH3, CST1, KLK6 and TRIM29 expression was upregulated in CRC. (C) Representative IHC images of TRIM29 expression. (D) Statistical data graph of patients with different TRIM29 expression levels in CRC tissues and noncancerous samples (P<0.0001). (E) Statistical data graph of patients with or without lymph node metastasis stratified by TRIM29 expression level (P=0.018). (F) Statistical data graph of patients at different stages stratified by TRIM29 expression level (P<0.0001). (G) Kaplan-Meier curves for CRC patients according to TRIM29 expression levels. The statistical analysis was performed using the chi-square test (P=0.005). (H) IHC results showed that TRIM29 is expressed at much higher levels in RSCC than in LSCC (P<0.0001). (I) qPCR was used to measure the relative expression levels of TRIM29 in CRC samples and their matched noncancerous samples (P<0.05). (J) The qPCR results showed that TRIM29 is expressed at much higher levels in RSCC than in LSCC (P<0.0001). (K) Western blotting was used to detect TRIM29 expression in 8 pairs of samples. The statistical analysis was performed using the chi-square test (DF, H) and two-tailed Student’s t-test (I, J). The error bars represent the SEM. Kaplan-Meier method compared with a log-rank test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001.